Literature DB >> 12574971

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

David M Goldenberg1, Chien-Hsing Chang, Robert M Sharkey, Edmund A Rossi, Habibe Karacay, William McBride, Hans J Hansen, Jean-Francois Chatal, Jacques Barbet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12574971     DOI： 10.1007/s00259-002-1089-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  32 in total

1.  New methods for localizing infection: a role for avidin-biotin?

Authors:  D A Goodwin
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

Review 2.  Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.

Authors:  J M Le Doussal; J Barbet; M Delaage
Journal:  Int J Cancer Suppl       Date:  1992

3.  Bullets to magic bullets--and miles to go before we sleep.

Authors:  A Lovqvist; C Divgi
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

Review 4.  Targeted therapy of cancer with radiolabeled antibodies.

Authors:  David M Goldenberg
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

5.  Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.

Authors:  E Gautherot; E Rouvier; L Daniel; E Loucif; J Bouhou; C Manetti; M Martin; J M Le Doussal; J Barbet
Journal:  J Nucl Med       Date:  2000-03       Impact factor: 10.057

6.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

8.  Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.

Authors:  D S Wilbur; D K Hamlin; R L Vessella; J E Stray; K R Buhler; P S Stayton; L A Klumb; P M Pathare; S A Weerawarna
Journal:  Bioconjug Chem       Date:  1996 Nov-Dec       Impact factor: 4.774

9.  Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin.

Authors:  T Saga; J N Weinstein; J M Jeong; T Heya; J T Lee; N Le; C H Paik; C Sung; R D Neumann
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

10.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Authors:  C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640
View more
  12 in total

1.  Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02       Impact factor: 9.236

2.  Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.

Authors:  Guozheng Liu; Jiang He; Shuping Dou; Suresh Gupta; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09       Impact factor: 9.236

3.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

4.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

Review 5.  Cancer radioimmunotherapy.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

6.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Authors:  Damian J Green; John M Pagel; Eneida R Nemecek; Yukang Lin; Aimee Kenoyer; Anastasia Pantelias; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Joseph G Rajendran; Ajay K Gopal; Steven I Park; Oliver W Press
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

7.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors:  David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal:  Update Cancer Ther       Date:  2007-03

8.  A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

Authors:  Damian J Green; Nural N Orgun; Jon C Jones; Mark D Hylarides; John M Pagel; Donald K Hamlin; D S Wilbur; Yukang Lin; Darrell R Fisher; Aimee L Kenoyer; Shani L Frayo; Ajay K Gopal; Johnnie J Orozco; Theodore A Gooley; Brent L Wood; William I Bensinger; Oliver W Press
Journal:  Cancer Res       Date:  2013-12-26       Impact factor: 12.701

9.  Pretargeted molecular imaging and radioimmunotherapy.

Authors:  David M Goldenberg; Chien-Hsing Chang; Edmund A Rossi; William J; Robert M Sharkey
Journal:  Theranostics       Date:  2012-05-17       Impact factor: 11.556

Review 10.  A pretargeting system for tumor PET imaging and radioimmunotherapy.

Authors:  Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Eric Frampas; Alain Faivre-Chauvet; Aurore Rauscher; Robert M Sharkey; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Journal:  Front Pharmacol       Date:  2015-03-31       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.